Surveillance Instead of Surgery for Low-Risk DCIS?.
What factors should patients consider when deciding between surveillance and surgery for low-risk DCIS?
Interview on Surveillance Rather of Surgery for Low-Risk DCIS
Time.news Editor (TNE): Thank you for joining us today to discuss the emerging approach of active surveillance for low-risk Ductal Carcinoma In Situ (DCIS). To start, could you explain what DCIS is and why it has become a focus of recent clinical trials?
Expert (E): Certainly! ductal Carcinoma in Situ is a non-invasive breast cancer that occurs when abnormal cells are found in the lining of the breast ducts. While it’s often considered a precursor to invasive breast cancer,many cases are low-risk and may not progress. Recent trials, such as the LORIS study, have explored the potential of active surveillance as an alternative to immediate surgery for women with low-risk DCIS. this approach allows for careful monitoring rather of opting for surgical intervention, especially if the cancer is assessed as unlikely to progress.
TNE: That sounds intriguing. What were the main findings of the recent research on this topic?
E: The LORIS trial indicated that many women with low-risk DCIS might be safely monitored without surgery, provided they are closely followed with regular assessments. It found that surgical interventions, such as mastectomy or lumpectomy, may not be necessary for all patients, especially for those who are at lower risk for progression.In fact, many patients reported feeling uncertainty about undergoing surgery, which highlights the importance of discussing all available options with their healthcare providers [1[1[1[1].
TNE: How dose this shift in approach impact patient care and decision-making?
E: This shift empowers patients by giving them more options. It allows for a shared decision-making process between patients and healthcare providers. Patients can weigh the benefits and risks of immediate surgery versus active monitoring, leading to a more personalized approach to their care. Education is vital here, as some women may feel pressured to proceed with surgery regardless of their comfort level or understanding of their diagnosis [2[2[2[2].
TNE: What advice would you give to patients who have been diagnosed with low-risk DCIS and are considering their treatment options?
E: Patients should thoroughly discuss their diagnosis with their oncologist and understand the implications of their specific situation. It’s crucial to ask questions about the likelihood of progression, the pros and cons of surgery versus active surveillance, and what regular monitoring would entail. Seeking a second opinion can also be beneficial. Patients should feel empowered to advocate for their health and make informed choices that align with their personal values and circumstances.
TNE: Lastly,how do you see the future of treating low-risk DCIS,especially as more studies are conducted?
E: I believe we are moving towards a more nuanced understanding of DCIS and its treatment. As more data from ongoing and future studies emerge, we can expect greater acceptance of active surveillance in clinical practice. It’s essential for future research to continue evaluating long-term outcomes and patient satisfaction to make evidence-based recommendations. This evolution will likely lead to more tailored treatment approaches in breast cancer care, enhancing the quality of life for many patients [3[3[3[3].
TNE: Thank you for sharing your insights today. This information is invaluable for our readers who are seeking clarity on the management of low-risk DCIS.
E: Thank you for having me! It’s crucial to continue these conversations and provide support to those navigating their options in breast cancer care.